ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 1691 • ACR Convergence 2025

    Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm

    Andrea Gutierrez1, Stephanie Armendariz2, Muniza Mogri3 and Kristina Ciaglia4, 1UT Southwestern Medical Center, Dallas, TX, 2Texas Scottish Rite Hospital, Dallas, TX, 3UT Southwestern Medical Center / Children’s Health Dallas, Dallas, TX, 4UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX

    Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at increased risk of low bone mineral density, with studies showing a 40% frequency of osteopenia (Lilleby,…
  • Abstract Number: 1549 • ACR Convergence 2025

    Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort

    Vasileios Kyttaris1, Dan Persons2, Gelareh Atefi3 and Mawuena Binka4, 1Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 2Trio Health, Louisville, CO, 3AstraZeneca, Wilmington, DE, 4Former Employee of AstraZeneca, Wilmington, DE

    Background/Purpose: Inflammatory arthritis is a cardinal manifestation of systemic lupus erythematosus (SLE), limiting joint mobility and adversely affecting quality of life.1 Joint activity in SLE…
  • Abstract Number: 1530 • ACR Convergence 2025

    The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus

    Guillermo Pons-Estel1, Rosana Quintana1, Romina Nieto1, Hermine Brunner2, Marina Scolnik3, Carmen Funes Soaje4, Paula Alba5, Veronica Saurit6, Mercedes Garcia7, GUILLERMO ARIEL BERBOTTO8, Inés Verónica Bellomio9, Mario Eduardo Kerzberg10, Graciela Gomez11, Cecilia Pisoni12, Vicente Juarez13, Ana Malvar14, Nélzio Silva15, ODIRLEI MONTICIELO16, Henrique Mariz17, Francinne Ribeiro18, Eduardo Borba19, Eloisa Bonfa19, Edgard Torres dos Reis-Neto20, Iris Guerra Herrera21, Maria Loreto Massardo22, Gustavo Aroca-Martínez23, Lorena Gómez Escorcia24, Carlos Alberto Cañas25, Gerardo Quintana-Lopez26, Carlos Toro-Gutierrez27, Mario Moreno Alvarez28, MIGUEL SAAVEDRA29, Margarita Portela Hernández30, Hilda Fragoso-Loyo31, Luis H Silveira32, Ignacio García-De la Torre33, Carlos Abud-Mendoza34, Jorge Antonio Esquivel Valerio35, Maria Isabel Acosta36, Astrid Paats37, Claudia S. Mora-Trujillo38, Manuel Ugarte-Gil39, Armando Calvo40, Roberto Muñoz-Louis41, Martin Rebella42, Alvaro Danza43, Federico Zazzetti44, Ashley Orillion45, Urbano Sbarigia46 and Bernardo A. Pons-Estel47, 1Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, 4Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 5Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 6Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, 7Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, 8Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, 9Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, 10Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, 11Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, 12CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, 13Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, 14Organización Médica de Investigación, Buenos Aires, Argentina, 15Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, 16Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, 17Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, 18Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, 19Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 20Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, 21Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, 22Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, 23Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, 24Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, 25Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, 26Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 27Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, 28Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, 29Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, 30Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, 31Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 32Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 33Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, 34Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, 35Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, 36Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, 37Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, 38Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, 39Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 40Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, 41Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, 42Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, 43Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, 44Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 45Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 46Johnson & Johnson, Beerse, Belgium, 47Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina

    Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e.…
  • Abstract Number: 1512 • ACR Convergence 2025

    Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients

    Takemichi Matsui1, Yumi Tsuchida2, Takahiro Itamiya2, Mineto Ota2, Toshihiko Komai2, Haruka Tsuchiya2, Hirofumi Shoda2, Tomohisa Okamura2 and Keishi Fujio2, 1Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Background/Purpose: With the introduction of anifrolumab to clinical practice, there is a growing interest in identifying factors associated with IFN activity in patients with SLE.…
  • Abstract Number: 1489 • ACR Convergence 2025

    Impact of Menopause on Long-Term Outcomes in Patients with Systemic Lupus Erythematosus

    Lorena López, José Bretón and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR

    Background/Purpose: Women of childbearing age are more prone to developing autoimmune diseases, suggesting a role for sex hormones, particularly estrogens, in regulating both cellular and…
  • Abstract Number: 1472 • ACR Convergence 2025

    Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort

    Amirtha Gopalan1, keerthi vardhan yerram2, Mahesh Gaikwad2 and Liza rajasekhar3, 1Nizams Institute of Medical Sciences, Hyderabad, Hyderabad, Telangana, India, 2Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, 3Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India

    Background/Purpose: LLDAS is a desirable state in lupus, with ongoing global reports on its durability and outcomes. The relationship between LLDAS, baseline characteristics, and drug…
  • Abstract Number: 1284 • ACR Convergence 2025

    Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus

    Daniel Clemente1, Alina-Lucica Boteanu2, Clara Udaondo3, Joan Calzada4, Juan Carlos Nieto5, Eugenia Enriquez6, Inmaculada Calvo7, Lourdes Villalobos8, Belen Sevilla9, Sara Murias10, Berta Magallares11, Ana Capilla12, Jaime Arroyo13, Beatriz Bravo14, Gisela Diez-Cordoves15, Marisol Camacho16, Genaro grana17, Juan Jose Bethencourt18, Pablo Mesa19, Natalia Palmou20, Mireia Lopez Corbeto21, Judith Sanchez22, Maria Isabel Gonzalez23, Clara Moriano24, Diego Dios17, Lorena Exposito25, Alicia Garcia26, Laura Martin27, David Fernandez28, Laura Trujillo14, Anahy Maria Brandy29, CARLOS GUILLEN-ASTETE30 and lydia Abasolo Alcazar31, 1Hospital Infantil Universitario NIño Jesús, Madrid, Madrid, Spain, 2H.U. Ramón y Cajal, Madrid, Spain, 3La Paz University Hospital, Madrid, Spain, 4University Hospital Sant Joan de Deu, Barcelona, Spain, 5Hospital General Universitario Gregorio Marañón, Madrid, Spain, 6Clínica Universidad de Navarra, Madrid, Spain, 7Hospital La Fe, Valencia, Comunidad Valenciana, Spain, 8Ramon y Cajal Hospital, MADRID, Spain, 9Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 10H.U Central de Asturias, Oviedo, Spain, 11Hospital de Sant Pau, Bareclona, 12H.U de La Merced, Sevilla, Spain, 13HOSPITAL UNIVERSITARIO LA PAZ, MADRID, 14H.U Virgen de Las Nieves, Granada, Spain, 15H. R. U. Malaga, Malaga, Spain, 16H.U. Virgen del Rocío, Sevilla, Spain, 17H.U de A Coruña, A Coruña, Spain, 18H.U. Canarias, Canarias, Spain, 19H.U Virgen de la Arrixaca, Murcia, Spain, 20H.U. marques de Valdecilla, Santander, Spain, 21H.U Vall d´Hebron, Barcelona, Spain, 22Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell (Spain)., Sabadell, Spain, 23H.U. La Fé, Valencia, Spain, 24Hospital León, LEON, Castilla y Leon, Spain, 25H.U Canarias, Canarias, Spain, 26Rheumatologist, La Laguna, Spain, 27H.R.U Malaga, Malaga, Spain, 28Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 29Hospital Germans Trias i Pujol, Badalona, Spain, 30H.U Ramón y Cajal, Madrid, Spain, 31IdISSC. HCSC, Madrid, Madrid, Spain

    Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in juvenile-onset systemic lupus erythematosus (jSLE) patients. We aimed to assess the…
  • Abstract Number: 1106 • ACR Convergence 2025

    Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan

    Ko-Jen Li1, Ting-Wei Chang2, Tso-Ting Lai3, Jui-Hung Kao4, TING-YUAN LAN5, Tai-Ju Lee6, pei-Hsinq lai7, Shao-Yu Pai8, Chiehyu Shen9 and Song-Chou Hsieh10, 1National Taiwan University Hospital, Taipei, Taiwan, 2National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, 3Naitional Taiwan University Hospital, Taipei, Taiwan (Republic of China), 4Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), 5National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, 6National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), 7Taipei City Hospital, Taichung, Taiwan, 8National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), 9National Taiwan University Hospital, Taipei city, Taiwan, 10National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)

    Background/Purpose: Hydroxychloroquine (HCQ) retinopathy is a progressive, vision-threatening retinal disease. While HCQ is typically discontinued after toxicity is detected, some patients undergo tapering due to…
  • Abstract Number: 0981 • ACR Convergence 2025

    GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases

    Christopher Moore1, Travis Drow2, Peter Cook2, Annaiz Grimm2, Victoria DeVault-Nelson1, Jennifer Mellen1, Payam Zarin1, Alaina Burgess1, Maegan Hoover1, Tingxi Guo1, Brock McKinney2, Noelle Dahl2, Aesha Vakil2, Brian Christin3, Gene Uenishi1, Tiffany Chen1, Alberto Del Rio-Espinola4, David Rawlings2 and Tom Wickham1, 1GentiBio, Cambridge, 2SCRI, Seattle, 3GentiBio, Seattle, 4GentiBio, Basel, Switzerland

    Background/Purpose: CD19 CAR T therapies have demonstrated promise in systemic lupus erythematosus (SLE) by transiently depleting B cells and resetting the immune system. However, long-term…
  • Abstract Number: 0927 • ACR Convergence 2025

    Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus

    Mir Howlader1 and Theresa Lu2, 1Weill Cornell Medical College, Brooklyn, NY, 2Hospital for Special Surgery, NEW YORK, NY

    Background/Purpose: Lupus is a chronic autoimmune disease with a global loss of self-tolerance. Lupus patients are photosensitive where exposure to even ambient sunlight results in…
  • Abstract Number: 0660 • ACR Convergence 2025

    Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study

    J. Michelle Kahlenberg1, Victoria Werth2, Joerg Wenzel3, John Schwarz4, Jinqi Liu4 and Brandon Johnson4, 1University of Michigan, Ann Arbor, MI, 2University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany, 4Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…
  • Abstract Number: 0637 • ACR Convergence 2025

    DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.

    Sundus Dwidar1, Mary Horton2, Meghan Nelson3, Joanne Nititham2, Richard Oppong3, Frank Donovan4, Jinoos Yazdany5, Maria Dall'Era6, Lisa Barcellos7, Heinner Guio8, Manuel Ugarte-Gil9, Lindsey Criswell2 and Cristina Lanata10, 1National Institutes of Health, Washington, 2NIH/NHGRI, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4National Institutes of Health, Bethesda, 5UCSF, San Francisco, CA, 6Division of Rheumatology, University of California, San Francisco, CA, 7UC Berkeley, Berkeley, 8Universidad de Huanuco, Lima, Peru, 9Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 10NIH/NHGRI, Bethesda

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that disproportionately affects individuals of Amerindian ancestry and those who self-identify as Hispanic. The term “Hispanic”…
  • Abstract Number: 0619 • ACR Convergence 2025

    Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects

    Luciana Parente Costa Seguro1, Andrea Negrini2, Sandra G Pasoto3, Nadia E Aikawa4, Ana C Medeiros-Ribeiro3, Eduardo Borba1, Emily Figueiredo Neves Yuki5, Artur Sartori2, Danieli Andrade6, Thiago Freitas7, Henrique Giardini7, Clovis Artur Silva8 and Eloisa Bonfa1, 1Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 4Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, 5Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, 6University of Sao Paulo, São Paulo, São Paulo, Brazil, 7Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, 8University of São Paulo, São Paulo, São Paulo, Brazil

    Background/Purpose: SLE patients are at increased risk of infections, including herpes zoster (HZ). Prior studies evaluating the recombinant herpes zoster vaccine (RZV) in SLE have…
  • Abstract Number: 0602 • ACR Convergence 2025

    Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022

    Ami Vyas1, Steven Cohen2 and Christine Eisenhower2, 1University of Rhode Island, Kingston, RI, 2University of Rhode Island, Kingston

    Background/Purpose: Limited information is available about the effect of systemic lupus erythematosus (SLE) on healthcare resource utilization and healthcare expenditures. The associations between SLE and…
  • Abstract Number: 0825 • ACR Convergence 2025

    Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules

    Sonam Kiwalkar1, Julianna Desmarais2, Ellen Snyder3, Lisa Schroeder4, Marissa Meissner5, Noelle A. Rolle6, Sarah Donohue7, Brittany Bettendorf8, Ira Khanna9, Karen Kruzer10, Nkechi Emejuaiwe11, Ibtissam Gad12, David Leverenz13, Michael George14, Ashima Makol15, Floranne Ernste15 and Jilie Blaszczak16, 1The Vancouver Clinic, Portland, OR, 2Oregon Health and Sciences University, Portland, OR, 3UNC Rheumatology, Chapel Hill, NC, 4Geisinger, Danville, PA, 5Geisinger Medical Center, Danville, PA, 6Medical College of Georgia at Augusta University, Evans, GA, 7University of Wisconsin, Madison, WI, 8University of Iowa, Iowa City, IA, 9Mount Sinai Hospital, New York, NY, 10Assistant Professor- University of Rochester, Victor, NY, 11Cincinnati VA Medical Center, Cincinnati, OH, 12University of Michigan, Plymouth, MI, 13Duke University, Durham, NC, 14University of Pennsylvania, Philadelphia, PA, 15Mayo Clinic, Rochester, MN, 16University of Michigan, Ann Arbor, MI

    Background/Purpose: Internal medicine (IM) residents often receive limited rheumatology training, contributing to low confidence in managing rheumatologic conditions and suboptimal performance on standardized examinations. Virtual…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology